A 52-Week, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Active Controlled, Phase IV Study to Evaluate the Safety and Efficacy of Dapagliflozin or Dapagliflozin Plus Saxagliptin Compared With Sulphonylurea All Given as Add-on Therapy to Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Monotherapy
A 52-Week, Multi-Centre, Randomised, Parallel-Group, Double-Blind, Active Controlled, Phase IV Study to Evaluate the Safety and Efficacy of Dapagliflozin or Dapagliflozin Plus Saxagliptin Compared With Sulphonylurea All Given as Add-on Therapy to Metformin in Adult Patients With Type 2 Diabetes Who Have Inadequate Glycaemic Control on Metformin Monotherapy
This study is being carried out to see if dapagliflozin and dapagliflozin plus saxagliptin as an addition to metformin is effective and safe in treating patients with type 2 diabetes when compared to glimepiride (sulphonylurea) as an addition to metformin treatment.
Inclusion Criteria: Main Inclusion Criteria:
Main, Exclusion Criteria:
Ostrava - Belsky Les, 700 30, Czechia
Plzen - Severni Predmesti, 301 00, Czechia
Kiel-Kronshagen, 24119, Germany
Mühldorf A. Inn, 84453, Germany
Neuwied Am Rhein, 56564, Germany
Rodgau-Dudenhofen, 63110, Germany
Orosháza-Szentetornya, 5900, Hungary